quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of Urban air mobility has long lived somewhere between science fiction and city planning decks…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence
  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence
  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence
  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence
  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence
  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence
  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence
  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence
  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence
  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence
  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of — Source | Via News | pt.VIA.NEWS